EUVIMEDEUVIMED entdecken
Crossref

Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised Individuals

Ghady Haidar iD, Jacob C Hodges, Andrew Bilderback, Amy Lukanski, Kelsey Linstrum, Barbara Postol, Rachel Troyan, Mary K Wisniewski, Lindsay Coughenour, Amy Heaps, Jana L Jacobs, Kailey Hughes Kramer und 19 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiad511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Ghady Haidar und 30 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Immunocompromised Host, COVID-19, Antibodies, Viral, COVID-19 Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Translational Science Institute;, DSF Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Improved coronavirus disease 2019 (COVID-19) prevention is needed for immunocompromised individuals.

Methods

A prospective study was performed of health care workers (HCW) and immunocompromised participants with baseline serology following 2 mRNA vaccine doses and who were retested after dose 3 (D3); multivariable regression was used to identify predictors of serological responses. IFN-γ/TNF-α T-cell responses were assessed in a subset.

Results

In total, 536 participants were included: 492 immunocompromised (206 solid organ transplant [SOT], 128 autoimmune, 80 hematologic malignancy [HM], 48 solid tumor, 25 HIV), and 44 HCW. D3 significantly increased spike IgG levels among all, but SOT and HM participants had the lowest median antibody levels post-D3 (increase from 0.09 to 0.83 and 0.27 to 1.92, respectively), versus HCW and persons with HIV, autoimmune conditions, and solid tumors (increases from 4.44 to 19.79, 2.9 to 15.75, 3.82 to 16.32, and 4.1 to 25.54, respectively). Seropositivity post-D3 was lowest for SOT (49.0%) and HM (57.8%), versus others (>90%). Neutralization post-D3 was lowest among SOT and HM. Predictors of lower antibody levels included low baseline levels and shorter intervals between vaccines. T-cell responses against spike increased significantly among HCW and nonsignificantly among immunocompromised individuals.

Conclusions

D3 significantly improves serological but not T-cell responses among immunocompromised individuals. SOT and HM patients have suboptimal responses to D3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunocompromised HostCOVID-19Antibodies, ViralCOVID-19 VaccinesSARS-CoV-2Immunity, CellularImmunity, HumoralHumansMaleFemaleProspective StudiesMiddle AgedAdultHealth PersonnelmRNA VaccinesT-LymphocytesAgedImmunoglobulin GInterferon-gamma

Stichwörter der Autor:innen

SARS-CoV-2 antibodyT cellsimmunocompromisedmRNA COVID-19 vaccineneutralization

Substanzen

Antibodies, ViralCOVID-19 VaccinesmRNA VaccinesImmunoglobulin GInterferon-gamma

Autor:innen und Institutionen

  • Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Wolff Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Internal Medicine Residency Program, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Clinical Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Ghady Haidar

Förderung

  • Translational Science Institute;
  • DSF Charitable Foundation

Zitieren

APA

Haidar, G., Hodges, J. C., Bilderback, A., Lukanski, A., Linstrum, K., Postol, B., Troyan, R., Wisniewski, M. K., Coughenour, L., Heaps, A., Jacobs, J. L., Hughes Kramer, K., Klamar-Blain, C., Kohl, J., Liang, W., Morris, B., Macatangay, B. J. C., Parikh, U. M., Sobolewksi, M. D., …, & Mellors, J. W. (2024). Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised Individuals. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad511

Vancouver

Haidar G, Hodges JC, Bilderback A, Lukanski A, Linstrum K, Postol B, et al. Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised Individuals. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad511

BibTeX
@article{Haidar2024,
  author = {Haidar, Ghady and Hodges, Jacob C and Bilderback, Andrew and Lukanski, Amy and Linstrum, Kelsey and Postol, Barbara and Troyan, Rachel and Wisniewski, Mary K and Coughenour, Lindsay and Heaps, Amy and Jacobs, Jana L and Hughes Kramer, Kailey and Klamar-Blain, Cynthia and Kohl, Joshua and Liang, Wendy and Morris, Benjamin and Macatangay, Bernard J C and Parikh, Urvi M and Sobolewksi, Michele D and Musgrove, Christopher and Crandall, Melissa D and Mahon, John and Mulvey, Katie and Collins, Kevin and King, Adam C and Wells, Alan and Zapf, Rachel and Agha, Mounzer and Minnier, Tami and Angus, Derek C and Mellors, John W},
  title = {Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised Individuals},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiad511}
}
Kostenlos starten →